Concourse Financial Group Securities, Inc. Cardiff Oncology, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 100.0%

22 transactions

Quarter	Operation	Price Per share
Q2 2025 Aug 12, 2025	BUY	$2.38 - $4.3 $0 - $0
Q1 2025 May 14, 2025	BUY	$3.14 - $4.75 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$2.31 - $5.35 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$2.05 - $2.77 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$2.22 - $5.89 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.46 - $5.91 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.96 - $1.55 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.38 - $2.18 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.38 - $2.18 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.37 - $1.95 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.45 - $2.09 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.22 - $1.66 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.54 - $3.21 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.17 - $2.61 $0 - $0
Q1 2022 May 09, 2022	BUY	$2.11 - $7.25 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$5.18 - $7.24 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$5.01 - $7.58 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$6.65 - $10.04 $0 - $0
Q1 2021 May 13, 2021	BUY	$9.1 - $19.57 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$12.02 - $24.71 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$4.25 - $14.19 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$0.78 - $5.1 $0 - $0

Others Institutions Holding CRDF

# of Institutions

126

Shares Held

22M

Call Options Held

966K

Put Options Held

208K

Vanguard Group Inc Valley Forge, PA

3.59M
Shares

$7.72 Million
0.0% of portfolio
Black Rock Inc. New York, NY

2.63M
Shares

$5.65 Million
0.0% of portfolio
Blair William & CO Chicago, IL

2.21M
Shares

$4.76 Million
0.01% of portfolio
Laurion Capital Management LP New York, NY

1.8M
Shares

$3.86 Million
0.11% of portfolio
Geode Capital Management, LLC Boston, MA

1.54M
Shares

$3.32 Million
0.0% of portfolio

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $93.2M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account